OTCMKTS:EMMBF

Emblem Competitors

$1.40

+0.02 (+1.45 %)

(As of 03/18/2019)

Add

Compare

Today's Range

$1.36

Now: $1.40▼

$1.45

50-Day Range

$1.40

MA: $1.40▼

$1.40

52-Week Range

$0.60

Now: $1.40▼

$1.63

Volume156,200 shs

Average Volume280,719 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Emblem (OTCMKTS:EMMBF) Vs. DDXS, TNGN, ATTBF, ADTX, AGNPF, and LBTSF

Should you be buying EMMBF stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Emblem, including (DDXS) (DDXS), (TNGN) (TNGN), Abattis Bioceuticals (ATTBF), ADiTx Therapeutics (ADTX), Algernon Pharmaceuticals (AGNPF), and Almirall (LBTSF).

Emblem vs. (DDXS) Stock

(DDXS) (OTCMKTS:DDXS) and Emblem (OTCMKTS:EMMBF) are both health technology companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Profitability

This table compares (DDXS) and Emblem's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(DDXS)	N/A	N/A	N/A
Emblem	N/A	N/A	N/A

Earnings and Valuation

This table compares (DDXS) and Emblem's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(DDXS)	N/A	N/A	N/A	N/A	N/A
Emblem	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for (DDXS) and Emblem, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(DDXS)	0	0	0	0	N/A
Emblem	0	0	0	0	N/A

Emblem vs. (TNGN) Stock

(TNGN) (OTCMKTS:TNGN) and Emblem (OTCMKTS:EMMBF) are both health technology companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Earnings and Valuation

This table compares (TNGN) and Emblem's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(TNGN)	N/A	N/A	N/A	N/A	N/A
Emblem	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares (TNGN) and Emblem's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(TNGN)	N/A	N/A	N/A
Emblem	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for (TNGN) and Emblem, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(TNGN)	0	0	0	0	N/A
Emblem	0	0	0	0	N/A

Emblem vs. Abattis Bioceuticals Stock

Emblem (OTCMKTS:EMMBF) and Abattis Bioceuticals (OTCMKTS:ATTBF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Earnings & Valuation

This table compares Emblem and Abattis Bioceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emblem	N/A	N/A	N/A	N/A	N/A
Abattis Bioceuticals	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Emblem and Abattis Bioceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emblem	N/A	N/A	N/A
Abattis Bioceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations for Emblem and Abattis Bioceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emblem	0	0	0	0	N/A
Abattis Bioceuticals	0	0	0	0	N/A

Emblem vs. ADiTx Therapeutics Stock

Emblem (OTCMKTS:EMMBF) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings for Emblem and ADiTx Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emblem	0	0	0	0	N/A
ADiTx Therapeutics	0	0	1	0	3.00

Earnings and Valuation

This table compares Emblem and ADiTx Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emblem	N/A	N/A	N/A	N/A	N/A
ADiTx Therapeutics	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Emblem and ADiTx Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emblem	N/A	N/A	N/A
ADiTx Therapeutics	N/A	N/A	N/A

Summary

ADiTx Therapeutics beats Emblem on 1 of the 1 factors compared between the two stocks.

Emblem vs. Algernon Pharmaceuticals Stock

Algernon Pharmaceuticals (OTCMKTS:AGNPF) and Emblem (OTCMKTS:EMMBF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares Algernon Pharmaceuticals and Emblem's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Algernon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Emblem	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Algernon Pharmaceuticals and Emblem, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Algernon Pharmaceuticals	0	0	0	0	N/A
Emblem	0	0	0	0	N/A

Profitability

This table compares Algernon Pharmaceuticals and Emblem's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Algernon Pharmaceuticals	N/A	N/A	N/A
Emblem	N/A	N/A	N/A

Emblem vs. Almirall Stock

Emblem (OTCMKTS:EMMBF) and Almirall (OTCMKTS:LBTSF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Emblem and Almirall's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emblem	N/A	N/A	N/A	N/A	N/A
Almirall	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Emblem and Almirall, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emblem	0	0	0	0	N/A
Almirall	0	1	1	0	2.50

Profitability

This table compares Emblem and Almirall's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emblem	N/A	N/A	N/A
Almirall	N/A	N/A	N/A

Summary

Almirall beats Emblem on 1 of the 1 factors compared between the two stocks.